# Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

> **NCT06786299** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia(AML)

## Interventions

- **BIOLOGICAL:** RD-IIT-001
- **DRUG:** CD84-CART

## Key facts

- **NCT ID:** NCT06786299
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06786299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06786299, "Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06786299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*